A newly published pilot study is the first to show that the selective estrogen receptor modulator (SERM) ospemifene effectively normalizes vestibular innervation sensitivity, in addition to confirming that it relieves postmenopausal vestibular signs and symptoms.

A lower-dose estradiol vaginal cream than is currently available in the United States was an effective and well-tolerated treatment for dyspareunia in postmenopausal women, according to a recent phase 3, randomized, multicenter, double-blind, placebo-controlled trial.

Higher levels of distress were linked to increased vaginal sexual symptoms, worry about dyspareunia, dissatisfaction with a relationship, and concerns about body image in a study looking at sexual well-being among cervical cancer survivors.

A 16-year-old girl presents to an emergency department (ED) accompanied by her boyfriend to report a 24-hour history of right lower quadrant pain. The pain is associated with midline lower back pain and light vaginal bleeding (1 to 2 tampons per day). She has experienced some nausea but no vomiting.